Wen Zhou

20210269939, Sep 2, 2021

Feb 26, 2021

17/186671

- Fremont CA, US
Weiguo Liu - Fremont CA, US
Wen Wan Zhou - Fremont CA, US
Sungnee George Chu - Fremont CA, US
Wei Zhang - Fremont CA, US

C30B 29/64
C30B 33/10
C30B 29/40
C30B 11/00
C30B 11/14

Methods and wafers for low etch pit density, low slip line density, and low strain indium phosphide are disclosed and may include an indium phosphide single crystal wafer having a diameter of 4 inches or greater, having a measured etch pit density of less than 500 cm, and having fewer than 5 dislocations or slip lines as measured by x-ray diffraction imaging. The wafer may have a measured etch pit density of 200 cmor less, or 100 cmor less, or 10 cmor less. The wafer may have a diameter of 6 inches or greater. An area of the wafer with a measured etch pit density of zero may at least 80% of the total area of the surface. An area of the wafer with a measured etch pit density of zero may be at least 90% of the total area of the surface.

20170212983, Jul 27, 2017

Oct 19, 2016

15/298219

- Pasadena CA, US
Sheel SHAH - Pasadena CA, US
Eric LUBECK - San Francisco CA, US
Wen ZHOU - Pasadena CA, US

G06F 19/20
G01N 21/78
G01N 21/64
C12Q 1/68
G06F 19/24

Disclosed herein are methods and systems for detecting and/or quantifying cellular targets such as nucleic acids in cells, tissues, organs or organisms. Through sequential barcoding, it is possible to perform high-throughput profiling of a large number of targets, such as transcripts and/or DNA loci. In some embodiments, error correction is implemented through use of barcodes that can tolerate mistakes and missing data during sequential hybridization of probes to selected targets.

20140329996, Nov 6, 2014

Mar 25, 2014

14/224274

- Lexington MA, US
Wen Zhou - Palo Alto CA, US
Robert J. Etches - San Mateo CA, US

SYNAGEVA BIOPHARMA CORP. - Lexington MA

A01K 67/027
C07K 16/02

5303881, 800 4, 800 19, 435349

Transgenes encoding exogenous antibodies are stably integrated into donor cells and are present in the somatic tissue of chimeric birds. The transgenes encode exogenous antibodies and are preferably expressed in the oviduct for collection in the egg. Tissue specificity is provided by selecting the content of the transgene accordingly. Birds whose genome is comprised of transgene-derived exogenous antibody-encoding DNA express exogenous antibodies having desirable chemical properties with increased therapeutic utility compared to antibodies derived from bacterial expression systems.